Navigation Links
Drug Company Seeks Approval for Human Testing of Vaccine against H5N1 Virus

British Drug company, PowerMed is seeking approval for conducting the first human trials of experimental vaccine against the deadly strain of avian flu virus H5N1//.

The World Health Organisation has reported 97 human cases of avian flu since December 2003, with at least 53 deaths.

The company has submitted its plans for the trial to the UK Medicines and Healthcare Products Regulatory Agency. The Agency is expected to approve the vaccine for the trial to proceed at a London hospital.

While the government has stockpiled antiviral drugs Tamiflu and Relenza against avian flu the vaccine could help to limit the infection's spread if a pandemic strain emerges. Unlike most other conventional vaccines that use weakened strains or fragments of the harmful virus, this test vaccine uses strands of DNA , making it a faster and more cost effective option.

During the trial, the volunteers are expected to be vaccinated with a handheld device that will blast harmless, microscopic gold particles coated in the vaccine into the upper arm at supersonic speeds.

Earlier this year tests of a DNA vaccine that was designed to give protection against seasonal flu showed that it offered 100% protection, based on the immune response of volunteers. The DNA vaccine against avian flu has been tested only in animals, so far, where it has proved successful.

According to John Beadle, chief medical officer of the Oxford-based company PowderMed, ‘Our tests have shown that it stops the infection entirely, to the point that we can't even measure the virus in the animals afterwards.’

The company's research has suggested that humans would require two doses of the vaccine, a prime and a boost. Half a kilogram of DNA would suffice for two doses of the vaccine for everyone in Britain.

The details of the trial are put up on the government's website, Clinicaltrials.gov where the company has statecd that was seeking 75 voluntee rs for the trial at Guy's drug research unit in London.

If the trial goes ahead as planned, volunteers will be tested over several months to monitor how long the vaccine remains effective. Preliminary results are expected in January next year.


'"/>




Related medicine news :

1. Problems Of a Growing Company
2. Teenagers Take More Risk-Taking Behaviors In The Company Of Same Sex Friends
3. Australian Company Gets $10 million For Developing Skin Cancer Gel
4. Elderly People Prefer The Company Of Pet Dogs
5. Ossur Acquires the U.S. Orthopaedics Company
6. Britain Approves Indian Company For Supplying Medicines
7. Drug Company Admits Knowledge Of Side Effects In Monkeys
8. Ranbaxy Expands By Acquiring A Generic Company In Belgium
9. Indian Training Company To Train Children In Dubai, Sharjah
10. GE Healthcare to Acquire Swedish Medical Company
11. New Company Will Seek Drugs Against Diabetes and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/20/2017)... ... ... With certifications and experience that puts them at the top of the field ... currently accepting new patients at their practice for these custom clear aligners. These qualified ... why they offer the latest in modern dental techniques to ensure that all their ...
(Date:6/20/2017)... ... June 20, 2017 , ... Many ... their regulatory principles, the research team developed expressRNA, a web platform encompassing computational ... This reveals at nucleotide resolution the ‘RNA maps’, which demonstrate that RBPs bind ...
(Date:6/20/2017)... ... June 20, 2017 , ... Total Security Integrated Systems, one ... the partner of choice by Amtrak to fulfill several projects in various Northeast ... long-distance intercity service in the contiguous United States. Security Executives at the company ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniworld Boutique River Cruise Collection ... latest all-inclusive boutique ship, S.S. Joie de Vivre . What really sets this ... France’s Seine River and designed small enough to dock directly in Paris. With The ...
(Date:6/20/2017)... ... June 20, 2017 , ... The law firm of Momkus McCluskey Roberts ... president of the DuPage County Bar Association’s Board of Directors. Cassioppi officially took on ... the Drake in Oak Brook. Momkus McCluskey Roberts LLC attorney Stacey A. McCullough was ...
Breaking Medicine News(10 mins):
(Date:5/29/2017)... 29, 2017  Cellect Biotechnology Ltd. (NASDAQ: ... enables the functional selection of stem cells, today provided ... first quarter ended March 31 st , 2017. ... in the first quarter of 2017," said Dr. Shai ... announced the treatment of the first blood cancer patient ...
(Date:5/23/2017)... 23, 2017  Leaf Healthcare, recognized for developing ... for pressure ulcer prevention, will unveil its comprehensive ... Critical Care Nurses, National Teaching Institute and Critical ... The Leaf Patient Monitoring System is the first ... environment.  The system seamlessly tracks patient movement throughout ...
(Date:5/18/2017)... , May 17, 2017  Bayer announced today that ... will be presented at the 53 rd Annual ... taking place June 2-6 in Chicago ... ASCO span prostate, colorectal, liver and thyroid cancers, as ... the Phase II CHRONOS-1 trial of copanlisib in patients ...
Breaking Medicine Technology: